Bruno Carlos
Sangro Gómez-Acebo
Catedrático de Universidad
Hospital Vall d'Hebron
Barcelona, EspañaHospital Vall d'Hebron-ko ikertzaileekin lankidetzan egindako argitalpenak (9)
2024
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU
Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432
2023
-
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
The Lancet. Oncology, Vol. 24, Núm. 12, pp. 1411-1422
-
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
ESMO Open, Vol. 8, Núm. 3
2022
-
Liver diseases: a sanitary and social challenge for Europe in the XXI Century. Results of EASL-Lancet Comission
Medicina Clinica
-
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
The Lancet, Vol. 399, Núm. 10319, pp. 61-116
2021
-
Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH
Medicina Clinica, Vol. 156, Núm. 9, pp. 463.e1-463.e30
2016
-
Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH
Medicina Clinica, Vol. 146, Núm. 11, pp. 511.e1-511.e22
2009
-
Diagnóstico y tratamiento del carcinoma hepatocelular
Medicina Clinica, Vol. 132, Núm. 7, pp. 272-287